about
Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cellsOptimizing radiotherapy protocols using computer automata to model tumour cell death as a function of oxygen diffusion processesImproved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer.ZEB1-responsive genes in non-small cell lung cancerSemaphorins and their receptors in lung cancer.Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.A new tissue segmentation method to calculate 3D dose in small animal radiation therapy.Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study.Validation of the analytical irradiator model and Monte Carlo dose engine in the small animal irradiation treatment planning system µ-RayStation 8BTumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacyInfluence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer ModelsReoxygenation during radiotherapy in intermediate-risk prostate cancer
P50
Q24550871-3DE0459E-16E4-46C3-A1D5-C5C7E9E0DEE9Q33720072-697A74E7-9B73-46AA-B29D-4DC55CBCF4E0Q35082792-658B5D0E-9E59-464C-9D88-9C74BA1E6E8BQ35915752-7D7FE89F-5486-4F82-B78A-B7DC2E77953EQ37072227-CF0D9FB2-6F61-4953-A671-A87457246C2BQ37588549-74A80A17-B037-42DE-8949-33D1AA2A686BQ39210021-C18934B2-B071-4D5C-8760-4EF731F56C85Q40079512-A423FB96-DAC4-4551-9BDE-84F3C404BDFEQ40108381-2555E2D4-9322-403D-8164-5948662F08F0Q50335101-5BA9E28C-B9CA-4DF1-85FA-EC52E4A34A4AQ52668175-1AD9801F-E992-4733-83E3-E2B929097658Q91916837-AC9F2A06-79EF-4DD3-BE81-AF03074BD839Q91949320-C26F669B-6E5C-44D9-9F67-5F2DDAA56E33Q92447612-A7179846-501D-4FCF-A66A-96AAD8F2B748Q92761660-FDC7A664-F243-4519-B98A-C553B5E681A1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vincent A Potiron
@ast
Vincent A Potiron
@en
Vincent A Potiron
@es
Vincent A Potiron
@nl
type
label
Vincent A Potiron
@ast
Vincent A Potiron
@en
Vincent A Potiron
@es
Vincent A Potiron
@nl
prefLabel
Vincent A Potiron
@ast
Vincent A Potiron
@en
Vincent A Potiron
@es
Vincent A Potiron
@nl
P106
P31
P496
0000-0002-3693-6578